AU2001226317A1 - Insulin-like growth factor system and cancer - Google Patents

Insulin-like growth factor system and cancer

Info

Publication number
AU2001226317A1
AU2001226317A1 AU2001226317A AU2631701A AU2001226317A1 AU 2001226317 A1 AU2001226317 A1 AU 2001226317A1 AU 2001226317 A AU2001226317 A AU 2001226317A AU 2631701 A AU2631701 A AU 2631701A AU 2001226317 A1 AU2001226317 A1 AU 2001226317A1
Authority
AU
Australia
Prior art keywords
insulin
cancer
growth factor
factor system
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001226317A
Other languages
English (en)
Inventor
Anastasia Diamandi
M. Javad Khosravi
Jehangir Mistry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnostic Systems Laboratories Inc
Original Assignee
Diagnostic Systems Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostic Systems Laboratories Inc filed Critical Diagnostic Systems Laboratories Inc
Publication of AU2001226317A1 publication Critical patent/AU2001226317A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001226317A 2000-01-18 2001-01-05 Insulin-like growth factor system and cancer Abandoned AU2001226317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09484903 2000-01-18
US09/484,903 US6448086B1 (en) 2000-01-18 2000-01-18 Insulin-like growth factor system and cancer
PCT/US2001/000397 WO2001053837A1 (fr) 2000-01-18 2001-01-05 Systeme de facteurs de croissance semblables a l'insuline (igf) et cancer

Publications (1)

Publication Number Publication Date
AU2001226317A1 true AU2001226317A1 (en) 2001-07-31

Family

ID=23926118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001226317A Abandoned AU2001226317A1 (en) 2000-01-18 2001-01-05 Insulin-like growth factor system and cancer

Country Status (3)

Country Link
US (3) US6448086B1 (fr)
AU (1) AU2001226317A1 (fr)
WO (1) WO2001053837A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064044A9 (en) * 1995-05-23 2008-03-13 Nelson Randall W Analysis of insulin-like growth factors from biological fluids by the use of affinity-based mass spectrometric methods
US6448086B1 (en) * 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
WO2002090580A1 (fr) * 2001-05-03 2002-11-14 National Cancer Centre Of Singapore Pte Ltd Identification du cancer du foie par detection de l'expression aberrante de proteines se liant au facteur de croissance analogue a l'insuline
WO2003061592A2 (fr) * 2002-01-22 2003-07-31 New York University Methodes de traitement therapeutique de l'hypertrophie benigne de la prostate (bph)
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
EP1575500A4 (fr) * 2002-07-12 2007-01-03 Univ Johns Hopkins Vaccins a la mesotheline et systemes de modele
CA2529759A1 (fr) * 2003-06-20 2005-10-13 University Of Florida Biomarqueurs permettant de differencier des diabetes de types 1 et 2
AU2011213758B2 (en) * 2004-02-19 2012-11-15 Yale University Identification of cancer protein biomarkers using proteomic techniques
JP4912894B2 (ja) 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
AU2008307634A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2008307579A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2400990A2 (fr) * 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2783665A1 (fr) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques predictifs d'une reponse anticancereuse aux inhibiteurs de kinase du recepteur du facteur de croissance insulinique 1
JP5932778B2 (ja) * 2010-05-28 2016-06-15 ビオメリューＢｉｏｍｅｒｉｅｕｘ 乳癌と良性乳房疾患を識別するための方法及びキット
ES2925983T3 (es) 2010-07-27 2022-10-20 Genomic Health Inc Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata
US10842849B2 (en) * 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
CN102590511B (zh) * 2012-02-14 2014-07-23 北京市肿瘤防治研究所 基于igfbp-2自身抗体或其与igfbp-2联合的检测的肿瘤诊断试剂或试剂盒及应用
JP6032470B2 (ja) * 2012-08-09 2016-11-30 富士レビオ株式会社 Ｐｉｖｋａ−ｉｉ測定方法、測定試薬及び測定キット
CN102830223A (zh) * 2012-08-14 2012-12-19 四川汇宇制药有限公司 一种筛选治疗哺乳动物肿瘤疾病药物的方法
EP2728441A1 (fr) 2012-10-31 2014-05-07 Thomson Licensing Dispositif et procédé de détection d'une panne de courant dans une alimentation électrique externe
EP3230314B1 (fr) 2014-12-08 2023-05-03 Berg LLC Utilisation de marqueurs comprenant de la filamine a dans le diagnostic et le traitement du cancer de la prostate
MX2017015700A (es) 2015-06-04 2018-11-09 Ospedale San Raffaele Srl Igfbp3 y sus usos.
MX367312B (es) 2015-06-04 2019-08-14 Ospedale San Raffaele Srl Inhibidor del eje igrbp3/tmem219 y diabetes.
CN108603883A (zh) * 2016-01-27 2018-09-28 富士胶片和光纯药株式会社 前列腺癌的判定方法
CN110954385B (zh) * 2019-12-17 2021-05-25 李惠 一种病理组织脱水仪

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
JP3904689B2 (ja) 1997-09-24 2007-04-11 日本ケミカルリサーチ株式会社 前立腺特異抗原の阻害剤
EP1057026A4 (fr) * 1998-01-21 2005-10-05 Brigham & Womens Hospital Facteur de croissance insulunoide i circulant et risque de developpement d'un cancer prostatique
US6248546B1 (en) 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
US6448086B1 (en) * 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer

Also Published As

Publication number Publication date
US20060121542A1 (en) 2006-06-08
US20030017513A1 (en) 2003-01-23
US6448086B1 (en) 2002-09-10
WO2001053837A1 (fr) 2001-07-26

Similar Documents

Publication Publication Date Title
AU2001226317A1 (en) Insulin-like growth factor system and cancer
AU1104901A (en) Patient-shielding and coil system
AU2001272928A1 (en) Distribution system
AU1995800A (en) Particle manipulation
AU7989400A (en) Compounds and methods
AU3215500A (en) Compounds and methods
AUPR030900A0 (en) Growth factor complex
AU2002342653A1 (en) Modified growth hormone
AU3924300A (en) Fibroblast growth factor-20
AU6173900A (en) Peptide transport
AU2001261366A1 (en) Advanced defrost system
AU2001282893A1 (en) Antenna structure and associated method
AU2002210725A1 (en) Watering system
AU2001272989A1 (en) Composting system
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2000277330A1 (en) Catheter system
AU2002218760A1 (en) Transport system
AU4688499A (en) Fibroblast growth factor receptor-5
AU5562100A (en) Irrigation method and system
AU2001272514A1 (en) Antenna system
AU2950200A (en) Artificial reef
AUPP885899A0 (en) Transport aid
AU4480101A (en) Delivery optimization system and method
AU3976600A (en) Improvements in partitioning systems
AU2621401A (en) Tracheotrode and tracheal electroventilation system